NGNENeurogene Inc.

Nasdaq neoleukin.com


$ 35.96 $ -2.48 (-6.45 %)    

Wednesday, 03-Jul-2024 12:59:57 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 35.98
$ 38.59
$ 0.00 x 0
$ 36.00 x 100
$ 35.96 - $ 38.69
$ 12.49 - $ 53.00
77,156
na
9.69M
$ 4.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-20-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-09-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-14-2016 12-31-2015 10-K
35 11-10-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-12-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

BMO Capital analyst Keith Tapper initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price ...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

Core News & Articles

High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data...

Core News & Articles

Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target ...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

Core News & Articles

As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to furth...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target fro...

Core News & Articles

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.14) by ...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $55 price target.

Core News & Articles

These data were presented during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. 

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $55 price target.

Core News & Articles

Leerink Partners analyst Mani Foroohar initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces ...

Core News & Articles

The data show that the NGN-401 gene therapy candidate has been generally well-tolerated, and there have been no treatment-emerg...

Core News & Articles

William Blair analyst Sami Corwin initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating.

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target fro...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $45 price target.

Core News & Articles

Neurogene Inc. (NASDAQ:NGNE) ("Neurogene" or "the Company"), a clinical-stage company founded to bring life-cha...